202 related articles for article (PubMed ID: 35346140)
1. The economic burden of pulmonary arterial hypertension in Spain.
Zozaya N; Abdalla F; Casado Moreno I; Crespo-Diz C; Ramírez Gallardo AM; Rueda Soriano J; Alcalá Galán M; Hidalgo-Vega Á
BMC Pulm Med; 2022 Mar; 22(1):105. PubMed ID: 35346140
[TBL] [Abstract][Full Text] [Related]
2. The direct and indirect health care costs associated with pulmonary arterial hypertension among commercially insured patients in the United States.
Ogbomo A; Tsang Y; Mallampati R; Panjabi S
J Manag Care Spec Pharm; 2022 Jun; 28(6):608-616. PubMed ID: 35621726
[No Abstract] [Full Text] [Related]
3. Economic Burden of Idiopathic Pulmonary Fibrosis in Spain: A Prospective Real-World Data Study (OASIS Study).
Rodríguez-Nieto MJ; Cano-Jiménez E; Romero Ortiz AD; Villar A; Morros M; Ramon A; Armengol S
Pharmacoeconomics; 2023 Aug; 41(8):999-1010. PubMed ID: 37249823
[TBL] [Abstract][Full Text] [Related]
4. The economic burden of disease of epithelial ovarian cancer in Spain: the OvarCost study.
Delgado-Ortega L; González-Domínguez A; Borrás JM; Oliva-Moreno J; González-Haba E; Menjón S; Pérez P; Vicente D; Cordero L; Jiménez M; Simón S; Hidalgo-Vega Á; Moya-Alarcón C
Eur J Health Econ; 2019 Feb; 20(1):135-147. PubMed ID: 29922900
[TBL] [Abstract][Full Text] [Related]
5. The economic burden of systemic sclerosis related pulmonary arterial hypertension in Australia.
Morrisroe K; Stevens W; Sahhar J; Ngian GS; Ferdowsi N; Hansen D; Patel S; Hill CL; Roddy J; Walker J; Proudman S; Nikpour M
BMC Pulm Med; 2019 Nov; 19(1):226. PubMed ID: 31775705
[TBL] [Abstract][Full Text] [Related]
6. The economic burden of chronic thromboembolic pulmonary hypertension in Russian Federation.
Chazova IE; Martynyuk TV; Valieva ZS; Nakonechnikov SN; Nedogoda SV; Salasyuk AS; Taran IN; Gratsianskaya SE
Ter Arkh; 2018 Sep; 90(9):101-109. PubMed ID: 30701743
[TBL] [Abstract][Full Text] [Related]
7. Cost of disorders of the brain in Europe 2010.
Gustavsson A; Svensson M; Jacobi F; Allgulander C; Alonso J; Beghi E; Dodel R; Ekman M; Faravelli C; Fratiglioni L; Gannon B; Jones DH; Jennum P; Jordanova A; Jönsson L; Karampampa K; Knapp M; Kobelt G; Kurth T; Lieb R; Linde M; Ljungcrantz C; Maercker A; Melin B; Moscarelli M; Musayev A; Norwood F; Preisig M; Pugliatti M; Rehm J; Salvador-Carulla L; Schlehofer B; Simon R; Steinhausen HC; Stovner LJ; Vallat JM; Van den Bergh P; van Os J; Vos P; Xu W; Wittchen HU; Jönsson B; Olesen J;
Eur Neuropsychopharmacol; 2011 Oct; 21(10):718-79. PubMed ID: 21924589
[TBL] [Abstract][Full Text] [Related]
8. Burden of pulmonary arterial hypertension in England: retrospective HES database analysis.
Exposto F; Hermans R; Nordgren Å; Taylor L; Sikander Rehman S; Ogley R; Davies E; Yesufu-Udechuku A; Beaudet A
Ther Adv Respir Dis; 2021; 15():1753466621995040. PubMed ID: 33620026
[TBL] [Abstract][Full Text] [Related]
9. Economic burden of locoregional and metastatic relapses in resectable early-stage non-small cell lung cancer in Spain.
De Castro J; Insa A; Collado-Borrell R; Escudero-Vilaplana V; Martínez A; Fernandez E; Sullivan I; Arrabal N; Carcedo D; Manzaneque A
BMC Pulm Med; 2023 Feb; 23(1):69. PubMed ID: 36809990
[TBL] [Abstract][Full Text] [Related]
10. Burden of Disease Study of Patients with Diabetic Macular Oedema in Spain.
Ruiz-Moreno JM; Gámez Lechuga M; Calvo P; Merino M; Martín Lorenzo T; Maravilla-Herrera P; Gil Jiménez B; Abraldes MJ
Ophthalmol Ther; 2024 May; ():. PubMed ID: 38771462
[TBL] [Abstract][Full Text] [Related]
11. [Pharmacoeconomic aspects of macitentan in the therapy of pulmonary arterial hypertension].
Moiseeva OM; Rudakova AV
Ter Arkh; 2017; 89(3):72-77. PubMed ID: 28378734
[TBL] [Abstract][Full Text] [Related]
12. Healthcare resource utilization and costs for patients with pulmonary arterial hypertension: real-world documentation of functional class.
Dufour R; Pruett J; Hu N; Lickert C; Stemkowski S; Tsang Y; Lane D; Drake W
J Med Econ; 2017 Nov; 20(11):1178-1186. PubMed ID: 28762848
[TBL] [Abstract][Full Text] [Related]
13. Economic burden of bilateral neovascular age-related macular degeneration: multi-country observational study.
Cruess AF; Zlateva G; Xu X; Soubrane G; Pauleikhoff D; Lotery A; Mones J; Buggage R; Schaefer C; Knight T; Goss TF
Pharmacoeconomics; 2008; 26(1):57-73. PubMed ID: 18088159
[TBL] [Abstract][Full Text] [Related]
14. The cost-effectiveness of bosentan in the United Kingdom for patients with pulmonary arterial hypertension of WHO functional class III.
Stevenson MD; Macdonald FC; Langley J; Hunsche E; Akehurst R
Value Health; 2009; 12(8):1100-5. PubMed ID: 19558373
[TBL] [Abstract][Full Text] [Related]
15. Burden of Disease Study of Patients with Neovascular Age-Related Macular Degeneration in Spain.
Abraldes MJ; Calvo P; Gámez Lechuga M; Merino M; Martín Lorenzo T; Maravilla-Herrera P; Gil Jiménez B; Ruiz-Moreno JM
Ophthalmol Ther; 2024 May; ():. PubMed ID: 38771461
[TBL] [Abstract][Full Text] [Related]
16. Economic evaluation of sildenafil for the treatment of pulmonary arterial hypertension in Indonesia.
Lilyasari O; Subekti Y; Atika N; Dinarti LK; Putri S; Opitasari C; Anggraini AB; Bussabawalai T; Teerawattananon Y
BMC Health Serv Res; 2019 Aug; 19(1):573. PubMed ID: 31412857
[TBL] [Abstract][Full Text] [Related]
17. Economic burden of multiple sclerosis in Slovakia - from 2015 to 2020.
Babela R; Dugas J
BMC Health Serv Res; 2022 Dec; 22(1):1467. PubMed ID: 36461018
[TBL] [Abstract][Full Text] [Related]
18. Cost effectiveness of prostacyclins in pulmonary arterial hypertension.
Roman A; Barberà JA; Escribano P; Sala ML; Febrer L; Oyagüez I; Sabater E; Casado MA
Appl Health Econ Health Policy; 2012 May; 10(3):175-88. PubMed ID: 22452448
[TBL] [Abstract][Full Text] [Related]
19. Healthcare resource utilization and costs in pediatric pulmonary arterial hypertension in a third-level hospital in Mexico.
García-Aguilar H; Vázquez SG; Trejo KS; Juárez YE; Juárez Vásquez KI; Sarmiento Sánchez ES; Molina HS
J Comp Eff Res; 2021 Nov; 10(16):1251-1257. PubMed ID: 34585624
[No Abstract] [Full Text] [Related]
20. Economic burden of multimorbidity among older adults: impact on healthcare and societal costs.
Picco L; Achilla E; Abdin E; Chong SA; Vaingankar JA; McCrone P; Chua HC; Heng D; Magadi H; Ng LL; Prince M; Subramaniam M
BMC Health Serv Res; 2016 May; 16():173. PubMed ID: 27160080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
